{"brief_title": "Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma", "brief_summary": "To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.", "condition": ["Sarcoma, Kaposi", "HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Mitoxantrone hydrochloride"], "criteria": "Inclusion Criteria Patients must have the following: - Biopsy proven Kaposi's sarcoma in advanced stages. - Positive HIV antibody, HIV culture or antigen capture or T4 cells < 500 in a patient with AIDS risk factor. - Informed consent and availability for follow-up. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Uncontrolled opportunistic infection. - Any medical, surgical or psychiatric condition which would constitute a contraindication to the use of mitoxantrone. Concurrent Medication: Excluded: - Zidovudine (AZT). Patients with the following are excluded: - Uncontrolled opportunistic infection. - Unable to give informed consent. - Any medical, surgical or psychiatric condition which would constitute a contraindication to the use of mitoxantrone. Prior Medication: Excluded: - More than one form of chemotherapy regimen. - Doxorubicin therapy > 300 mg/m2. Prior Treatment: Excluded: - Previous therapy consisting of more than one modality of therapy (e.g., chemotherapy plus radiotherapy or more than one form of chemotherapy regimen.)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Acquired Immunodeficiency Syndrome", "mesh_term": ["HIV Infections", "Sarcoma", "Sarcoma, Kaposi", "Mitoxantrone"], "id": "NCT00002259"}